DRDO's Anti-COVID-19 drug '2DG' launched in India
The drug for COVID-19 treatment has been developed by DRDO'sInstitute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy's Labratories.
NEW DELHI:
The first batch of 2-deoxy-D-glucose (2DG) anti-COVID drug developed by the Defence Research and Development Organisation (DRDO) was launched by Defence Minister Rajnath Singh and Health Minister Dr Harsh Vardhan on Monday.
The drug for COVID-19 treatment has been developed by DRDO's Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr. Reddy's Laboratories (DRL).
"Handed over the first batch of 2-D anti-Covid drug to the Union Health Minister @drharshvardhan after it was released today. This 2-DG drug developed by @DRDO_India & DRL is a perfect example of India's scientific prowess and a milestone in the efforts towards self-reliance," Defence Minister Rajnath Singh tweeted.
Similarly, Dr Harsh Vardhan took to Twitter and said, 'Pleased to have joined Minister of @DefenceMinIndia, Sh @rajnathsingh Ji today for the release of 1st batch of 2DG drug. Indigenously developed by @DRDO_India, the anti-#COVID19 therapeutic will reduce recovery time & supplementary oxygen dependency among patients."
The first batch of 10,000 doses of 2DG medicine would be launched early next week, the Defence Minister informed.
The drug will be a big boost to India's fight against the COVID pandemic and will be of immense benefit to the people suffering from COVID-19.
The DRDO had been working with its industry partner DRL for the development of the drug for some time.
(Edited by Shankar Kumar Turha)
ALSO READ: India reports lowest COVID-19 cases in 26 days, 2.81 lakh infections in last 24 hours
TNT-The Northeast Today is now on WhatsApp. CLICK HERE to receive more updates on your phone.
